Chronic lymphocytic leukemia/small lymphocytic lymphoma

This phase 2 trial tests an oral drug called nemtabrutinib in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) whose cancer has stopped responding to other targeted therapies. Participants take nemtabrutinib once daily in 28-day cycles until the …

Researchers are testing whether a fixed course of two oral drugs, zanubrutinib and sonrotoclax, can shrink chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back after earlier treatment. The trial enrolls about 44 adults whose cancer progressed …

This phase III trial is testing whether an experimental drug called TQB3909 can help people with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) whose disease has returned or stopped responding to prior treatments. Participants will be randomly assigned to re…

This phase II trial is testing whether a combination of two targeted drugs—pirtobrutinib and sonrotoclax—can shrink tumors in people with three types of B-cell lymphoma: transformed diffuse large B-cell lymphoma, relapsed or refractory chronic lymphocytic leukemia/small lymphocyt…

This Phase 2 trial tests lisaftoclax, an oral drug that blocks a protein helping cancer cells survive. It enrolls 75 adults with certain slow-growing lymphomas (CLL, WM, or MZL) who either cannot take standard BTK inhibitors due to health issues or have stopped them due to side e…

This phase 2 trial tests a treatment plan for people with newly diagnosed chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Participants first take zanubrutinib alone for 12 cycles, then add sonrotoclax for another 12 cycles. The goal is to see if this seque…

This Phase II trial will test a combination of pomalidomide, an anti-CD20 antibody, and prednisone as a first treatment for people with indolent (slow-growing) B-cell lymphomas. About 30 adults who have not had prior therapy will receive six cycles of the combo, followed by two y…

This phase 2 trial tests a combination of three drugs—acalabrutinib, venetoclax, and tafasitamab—in 35 people with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma. The goal is to see if this mix is safe and can lead to a complete response with very…

This early study tests a new drug called MTM-H-001 in 69 adults with B-cell blood cancers (like certain lymphomas and leukemias) that have come back or stopped responding to treatment. The main goal is to check safety and find the right dose, while also seeing if it can shrink tu…

This study tests a combination of two drugs, pomalidomide and obinutuzumab, in people with slow-growing lymphomas (like follicular lymphoma) that have returned or not responded to prior therapy. The first part finds the safest dose, and the second part checks how well the combina…

This early study tests a new treatment for people with B-cell blood cancers that have come back or not responded to standard therapy. The treatment uses donor immune cells (CAR-T cells) designed to find and attack cancer cells. The main goal is to check if it's safe, with a small…

This early-stage study tests a new drug called QLS2313 in 124 adults with blood cancers (like lymphoma or leukemia) that returned or didn't respond to standard treatments. The main goal is to check safety and find the right dose, not to cure the disease. Participants receive the …

This early-phase trial is testing an experimental drug called MS-553 in 12 adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back or stopped responding to treatment. The main goal is to check the drug's safety and find the right dose…

This study will check for a mutation in the Notch1 gene in blood or bone marrow samples from 80 people with chronic lymphocytic leukemia (CLL) or non-Hodgkin's lymphoma (NHL). The goal is to see how common this mutation is and compare it between the two cancers. This is an observ…